NurExone Biologic Inc. announced in October 2023, to expand the Company's portfolio, is now officially underway. This collaboration, aimed at combining Inteligex's more than twenty years of experience in cell-based therapies and NurExone's innovative exosome platform to develop therapies for patients with chronic spinal cord injuries, was approved for grant funding, to be disbursed over the course of the next two years, by the Israel-Canada bilateral Eureka program.